6 October 2022

Wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. completes phase II clinical trial patient recruitment - Trial to commence shortly

Highlights:

- **Halucenex successfully recruits 20 patients for clinical trial**
- **Clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD)**
- **Trial participants have an average age of 43 and include veterans, police officers, fire fighters, emergency medical responders and solicitors amongst others**
- **All participants have PTSD and also suffer from other mental health disorders including (but not limited to) anxiety, depression, anxiety, ADHD, OCD and addiction**
- **Trial to commence 12 October 2022 and complete 14 December 2022**
- **Company to utilise its Lucenex branded 10mg and 25mg synthetic psilocybin product formulation throughout the trial**
- **Treatment facilities across Canada now being prepared for first dosages to be administered**
- **Post trial Halucenex anticipates that it will have sufficient data to potentially advance product development, licencing agreement and regulatory approvals**
- **Potential success in the trial will allow Halucenex to access to the PTSD therapeutics sector which is expected to grow to US$10.5Bn in value by 2025[i]**

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to report that wholly-owned, Canadian based psychedelics company, Halucenex Life Sciences Inc. ("Halucenex") has successfully recruited 20 patients for its phase II clinical trial, which will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).

The proposed phase II clinical trial is designed to be a single-arm, open-lab trial that will ultimately determine the feasibility of future trials of psilocybin in this indication. The trial will be undertaken in line with Halucenex's Clinical Trial Authorisation, awarded by Health Canada earlier in the year (refer ASX announcement: 28 February 2022).

Completion of the patient recruitment process followed a number of inquiries from local and international individuals suffering from PTSD and an extensive review of all background from each candidate's application.

The patients include a number of veterans, Royal Canadian Mounted Police, fire fighters, Emergency Medical Responders, psychologists, security officers and attorneys, amongst other occupations. While each participant has symptoms associated with PTSD, each also suffers from other mental illnesses including anxiety, suicidal thoughts, ADHD, OCD, depression, anger and anxiety amongst others.

This unique patient cohort provides Halucenex with the potential to test its synthetic psilocybin product on a broad range of individuals, suffering from a number of debilitating conditions.

Halucenex will commence the trial on 12 October 2022, following the administration of first dosages to patients. As part of the initiative, Halucenex will utilise its 100%-owned and formulated synthetic psilocybin aqueous solution Lucenex, in both 10mg and 25mg formats. The Company expects the trial to complete by 14 December 2022.

Upon completion and subject to success in the trial, the Company will review all associated data to assess potential product development opportunities, licencing agreements, regulatory registrations and ongoing R&D into the use of synthetic psilocybin on PTSD and other conditions.

Commentary:

Halucenex CEO and Founder Mr Bill Fleming said: *"The Company has been receiving a steady stream of inquiries since news of the trial was announced and we are very pleased to have completed the patient recruitment process in such an efficient manner.*

"Halucenex will now begin preparing its relevant treatment facilities for first dosages, which will be administered within the next two weeks. Clinical trial participants will be closely monitored closely and in line with all Health Canada regulations.

"We look forward to providing additional updates as the trial commences, initial dosages are administered and ultimately, interim results that will highlight how synthetic psilocybin can be used to treat such a debilitating condition."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Directors of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries
Creso Pharma Limited
E: info@cresopharma.com
P: +61 (0) 497 571 532

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Creso Pharma offices:

Australia
Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Switzerland
Allmendstrasse 11, 6310 Steinhausen, Schweiz

Canada
59 Payzant Driver, Windsor, Nova Scotia, B0N 2TO and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2TO

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

[i] Credence Research PTSD Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018-2026